Patients with ovarian cancer who have germline or somatic BRCA1 or BRCA2 mutations, or those patients with high levels of genomic scarring, a hallmark of HRD, have been shown to have better response rates and longer progression-free survival when treated with PARP inhibitors [28,29]. This evidence concerns the gene PARP1 and ovarian carcinoma.